To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide: Additional Phase III data

Additional data from the double-blind, U.S. Phase III CALGB-100104 trial in 460 subjects showed that 5-15 mg/day Revlimid as maintenance therapy following autologous stem cell transplantation met the secondary

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE